0000904454-19-000460.txt : 20190604 0000904454-19-000460.hdr.sgml : 20190604 20190604140740 ACCESSION NUMBER: 0000904454-19-000460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190603 FILED AS OF DATE: 20190604 DATE AS OF CHANGE: 20190604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Astley-Sparke Philip CENTRAL INDEX KEY: 0001376491 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 19876057 MAIL ADDRESS: STREET 1: C/O BIOVEX GROUP, INC. STREET 2: 34 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 10801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-06-03 0001590560 uniQure N.V. QURE 0001376491 Astley-Sparke Philip C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 1105BP NETHERLANDS 1 0 0 0 Ordinary Shares 2019-06-03 4 S 0 400 61.40 D 18872 D Ordinary Shares 2019-06-03 4 S 0 600 62.97 D 18272 D Ordinary Shares 2019-06-03 4 S 0 4401 63.80 D 13871 D Ordinary Shares 2019-06-03 4 S 0 599 64.53 D 13272 D The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $61.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.35 to $63.28. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.36 to $64.28. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.40 to $64.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christian Klemt, Attorney-in-Fact 2019-06-04